Daridorexant hydrochloride

盐酸达利雷生

Report date: 2026/04/21 20:00:18
NME

Base Information

Drug NameDaridorexant hydrochloride
Drug Alias Name达利雷生DORADaridorexant达里多生奈莫雷生 +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionOrexin receptor type 1 antagonistsOrexin receptor type 2 antagonists
TargetsOrexin receptor type 1Orexin receptor type 2
Therapy Area/IndicationsStress Disorders, Post-TraumaticAlcoholismPostoperative Cognitive Complications +[10] 
Global Approved IndicationsSleep Initiation and Maintenance Disorders
Approved Indications in ChinaSleep Initiation and Maintenance Disorders
Original Approved Country/TerritoryUnited States
Original Approved Date2022/01/07
Country/TerritoryCzechiaBelgiumBulgaria +[23] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesActelion Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNxera Pharma Korea Co LtdIdorsia LtdGlobal Coalition For Adaptive Research Inc +[12] 
Inactive CompaniesFareva AmboiseFarmea
Active IndicationsStress Disorders, Post-TraumaticAlcoholismPostoperative Cognitive Complications +[7] 
Inactive IndicationsRenal InsufficiencyPulmonary Disease, Chronic ObstructiveHepatic Insufficiency

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG